Log In
BCIQ
Print this Print this
 

LT-02

  Manage Alerts
Collapse Summary General Information
Company Lipid Therapeutics GmbH
DescriptionControlled-release formulation of phosphatidylcholine that augments the natural protective mucosal barrier in the lower gut
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat mesalazine-refractory ulcerative colitis (UC)
Regulatory Designation
PartnerDr. Falk Pharma GmbH;
Nestle S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
Get a free BioCentury trial today